Question Title * 1. Please provide the name of the organization (hospital, university, health system, etc.) that you work for. Question Title * 2. What degree best describes you? RN NP MD/DO Other (please specify) Question Title * 3. A moderate risk of anemia in patients with CLL is associated with which of the following agents: A. Bendamustine B. Clofarabine C. Obinutuzumab + Chlorambucil D. Alemtuzumab E. All of the above F. A and B only Question Title * 4. CLL patient risk factors for infection include which of the following: A. Prior chemotherapy or radiation therapy B. Persistent neutropenia C. Bone marrow involvement with CLL D. Recent surgery and/or open wounds E. Liver dysfunction F. Renal dysfunction G. Age <65 H. All of the above I. All but g Question Title * 5. Which agent has the highest emetogenic potential in patients with CLL? Alemtuzumab Bendamustine Ofatumumab Obinutuzumab All of the above Question Title * 6. Which factors are the most critical for directing therapy in patients with relapsed/refractory CLL? A. Prior treatment B. Presence of del(17p) C. Presence of mutated TP53 D. Age E. All of the above F. B and C only Question Title * 7. True or false: In patients with CLL/SLL, Grade 1 fatigue is an indication for treatment. True False Done